Key Points
- Director Jeffrey Graves bought 9,000 shares on Nov. 5 at $11.35 each for $102,150, increasing his holding to 41,086 shares (a 28.05% rise), as disclosed in an SEC filing.
- Integra reported quarterly EPS of $0.54 (vs. $0.43 consensus) but revenue missed at $402.06M (vs. $414.31M) and the company still shows a negative net margin of 30.87%; management set Q4 2025 EPS guidance of $0.79–$0.84 and FY2025 of $2.19–$2.24.
- Analyst sentiment is bearish overall—MarketBeat lists an average rating of "Reduce" with a $15.83 consensus target after several firms cut price targets and issued sell/underweight ratings, while institutional ownership remains high at 84.78%.
Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) Director Jeffrey Graves acquired 9,000 shares of the business's stock in a transaction that occurred on Wednesday, November 5th. The shares were purchased at an average cost of $11.35 per share, for a total transaction of $102,150.00. Following the acquisition, the director owned 41,086 shares in the company, valued at $466,326.10. This represents a 28.05% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Integra LifeSciences Stock Performance
Integra LifeSciences stock opened at $11.22 on Friday. Integra LifeSciences Holdings Corporation has a 1 year low of $10.87 and a 1 year high of $27.13. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. The company has a market capitalization of $873.95 million, a P/E ratio of -1.72 and a beta of 1.20. The business has a 50 day moving average of $14.44 and a 200-day moving average of $13.70.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.11. The firm had revenue of $402.06 million during the quarter, compared to the consensus estimate of $414.31 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The company's revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.41 earnings per share. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS. FY 2025 guidance at 2.190-2.240 EPS. On average, equities research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.
Analysts Set New Price Targets
Several research firms have issued reports on IART. Weiss Ratings restated a "sell (d)" rating on shares of Integra LifeSciences in a report on Wednesday, October 8th. Truist Financial reissued a "hold" rating and set a $13.00 target price (down previously from $15.00) on shares of Integra LifeSciences in a research note on Monday. JPMorgan Chase & Co. upped their price target on shares of Integra LifeSciences from $12.00 to $13.00 and gave the company an "underweight" rating in a research report on Friday, October 31st. Finally, Citigroup dropped their price objective on Integra LifeSciences from $12.00 to $11.00 and set a "sell" rating on the stock in a research note on Friday, October 31st. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and four have given a Sell rating to the company. According to MarketBeat, Integra LifeSciences has an average rating of "Reduce" and a consensus target price of $15.83.
Get Our Latest Report on Integra LifeSciences
Institutional Investors Weigh In On Integra LifeSciences
Hedge funds have recently added to or reduced their stakes in the company. Rubric Capital Management LP raised its position in shares of Integra LifeSciences by 58.4% during the second quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company's stock worth $90,233,000 after purchasing an additional 2,710,262 shares during the period. Paradigm Capital Management Inc. NY increased its position in shares of Integra LifeSciences by 57.5% during the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company's stock worth $26,767,000 after acquiring an additional 796,300 shares in the last quarter. Access Investment Management LLC bought a new stake in shares of Integra LifeSciences during the second quarter worth about $5,348,000. Soleus Capital Management L.P. raised its holdings in shares of Integra LifeSciences by 29.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 1,387,818 shares of the life sciences company's stock worth $17,029,000 after acquiring an additional 315,614 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in Integra LifeSciences by 10.4% during the 1st quarter. Wellington Management Group LLP now owns 2,766,125 shares of the life sciences company's stock worth $60,827,000 after purchasing an additional 259,987 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.
Integra LifeSciences Company Profile
(
Get Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
